Clinical Trials Update: Jan. 16, 2007
Cervical Dysplasia or Human Papilloma Virus (HPV) Alzheimer's Disease Cancer Pain
(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:
Cervical Dysplasia or Human Papilloma Virus (HPV)
Have you recently had an abnormal pap test or been told that you have cervical HPV (human papillomavirus)? If so, you may qualify for an investigational study to evaluate the eradication of HPV infection after using an investigational gel applied intravaginally. Women 18-45 who are willing to be on an acceptable method of birth control, have a screening pap test of low-grade squamous intraepithelial lesions (LSIL) or atypical squamous cells of undetermined significance (ASC-US), and are high-risk HPV positive may qualify. The study will last approximately 27 months and involve up to 16 clinic visits.
The research sites are located throughout the United States and Canada.
This study will test the effectiveness of the study medication as an add-on therapy to current Alzheimer's medication. Volunteers 50-90 who have a probable diagnosis of Alzheimer's disease and have been receiving at least six months of ongoing treatment for Alzheimer's may be included. Patients must have a caregiver who is willing to attend all visits, oversee patient compliance, and report on patient status. Participants may not be diagnosed with vascular dementia, or have a history of any other CNS disorder (stroke, hemorrhage, epilepsy, Parkinson's, etc.). Other criteria apply.
The research site is in Little Rock, Ark.
This study will evaluate an experimental drug for breakthrough pain. Candidates at least 18 may be included who have cancer-related pain, are not pregnant or breastfeeding, and do not have a cardiopulmonary disease that would increase risk of shortness of breath.
The research site is in New York, NY.
Copyright 2007 Thomson CenterWatch. All rights reserved.